跳至主要内容
临床试验/NL-OMON25460
NL-OMON25460尚未招募不适用

A prospective, open-label, non-interventional phase IV study to investigate the COgnitive status, MOod, fatigue and quality of life in relapsing remitting multiple sclerosis patients treated with teriflunomide (Aubagio®) in Daily routine Observational Setting.

未提供0 个研究点目标入组 120 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Patients with RRMS according the McDonald criteria 2010 and approved SmPC of Aubagio
  • Treatment naïve RRMS patients or currently being treated with Aubagio for no more than 2 month or previously treated (with other first-line DMDs) with a wash-out period according to the respective SmPC before starting Aubagio. (verification has occurred prior to study enrollment)

排除标准

  • Severe disability and/or any neurological or severe psychiatric disorder, history of alcohol/ drugs abuse, history of traumatic brain injury with residual symptoms which might interfere with cognitive performance and other questionnaire outcomes

研究者

发起方
未提供

相似试验